Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Bioniche Appoints CEO | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Bioniche Appoints CEO

Berendt replaces McRae, who plans to retire

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Michael Berendt has been appointed chief executive officer of Bioniche Life Sciences Inc. Dr. Berendt replaces Graeme McRae, who plans to retire and assume the role of founder and chairman emeritus of the board of directors.
 
Dr. Berendt has held positions of increasing responsibility in the U.S. research departments at Pfizer and Bayer Corp. He also served as managing director of the Life Sciences Sector of AEA Investors, and managing director of Research Corporation Technologies. In 2006, he became the president and chief executive officer of Aegera, which was sold to Pharmascience in 2011.
 
“The board of directors, management team, employees and shareholders acknowledge Graeme’s significant contribution, while welcoming Dr. Berendt to the Bioniche team,” said James Rae, chairman at Bioniche Life Sciences. “Dr. Berendt has an established background in the life sciences sector, most recently serving as president and chief executive officer of Aegera Therapeutics Inc. in Montréal, Québec.”
 
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters